These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29976689)

  • 21. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome Engineering for Stem Cell Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
    Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
    Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
    Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
    J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
    Li XL; Li GH; Fu J; Fu YW; Zhang L; Chen W; Arakaki C; Zhang JP; Wen W; Zhao M; Chen WV; Botimer GD; Baylink D; Aranda L; Choi H; Bechar R; Talbot P; Sun CK; Cheng T; Zhang XB
    Nucleic Acids Res; 2018 Nov; 46(19):10195-10215. PubMed ID: 30239926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Base Editing Systems Are Available for Plants.
    Marzec M; Hensel G
    Trends Plant Sci; 2018 Nov; 23(11):955-957. PubMed ID: 30224156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temperature effect on CRISPR-Cas9 mediated genome editing.
    Xiang G; Zhang X; An C; Cheng C; Wang H
    J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The genome editing revolution: A CRISPR-Cas TALE off-target story.
    Stella S; Montoya G
    Bioessays; 2016 Jul; 38 Suppl 1():S4-S13. PubMed ID: 27417121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting.
    Chen F; Ding X; Feng Y; Seebeck T; Jiang Y; Davis GD
    Nat Commun; 2017 Apr; 8():14958. PubMed ID: 28387220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.
    Kaur B; Perea-Gil I; Karakikes I
    Curr Cardiol Rep; 2018 Jun; 20(7):58. PubMed ID: 29860642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
    Chaterji S; Ahn EH; Kim DH
    Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
    Chadwick AC; Musunuru K
    Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The CRISPR/Cas system: a genome editing tool to develop animal models of viral infections].
    Castino G; Guillemet M; Joly A; Vignon A
    Med Sci (Paris); 2018 May; 34(5):403-405. PubMed ID: 29900841
    [No Abstract]   [Full Text] [Related]  

  • 38. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era of gene editing for the treatment of human diseases.
    Kc M; Steer CJ
    Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome Editing for Cardiovascular Diseases-A Brief Review for Cardiologists.
    Hagiwara N
    Am J Cardiol; 2019 Mar; 123(6):1002-1006. PubMed ID: 30606452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.